|
|
Blood, Vol. 108, Issue 5, 1733-1743, September 1, 2006
Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma
Blood Walker et al.
108: 1733
Supplemental materials for: Walker et al
Chromosome 13 Gene Expression Clustering
We clustered expression data according to LOH of the whole of chromosome 13 and identified 51 genes differentially expressed on 13q, of which three were over-expressed and 48 were under-expressed (Table S2). Lower RB1 expression levels were not only restricted to cases with del(13). However, samples containing t(11;14) without del(13) showed higher RB1 expression. Using del(13) as a marker, we sought to identify a pattern of gene expression typical of this group. Hierarchical clustering analysis identified 51 deregulated genes associated with deletion of chromosome 13. We identified two genes with a possible tumor suppressor role, DNAJD1 and TSC22D1. DNAJD1 is inactivated in ovarian cancer and malignant pediatric brain tumors and TSC22D1 has been suggested to act as a tumor suppressor gene in myeloma and astrocytomas.1-4 1. Kelly T, Miao HQ, Yang Y, et al. High heparanase activity in multiple myeloma is associated with elevated microvessel density. Cancer Res. 2003;63:8749-8756.
2. Lindsey JC, Lusher ME, Strathdee G, et al. Epigenetic inactivation of MCJ (DNAJD1) in malignant paediatric brain tumours. IntJCancer. 2006;118:346-352.
3. Shostak KO, Dmitrenko VV, Garifulin OM, et al. Downregulation of putative tumor suppressor gene TSC-22 in human brain tumors. JSurgOncol. 2003;82:57-64.
4. Shridhar V, Bible KC, Staub J, et al. Loss of expression of a new member of the DNAJ protein family confers resistance to chemotherapeutic agents used in the treatment of ovarian cancer. Cancer Res. 2001;61:4258-4265.
Files in this Data Supplement:
|
|
